Our Impact
With the launch of GBM AGILE, a new path has been uncovered—one that accelerates this pace of discovery from bench to bedside, and offers the greatest hope in the fight against cancer. Many important milestones have already been achieved, but there’s so much more on the horizon. Take a look and see how the generous support of our donors is making a difference, one dollar at a time.
“Donors are the linchpin. Not only do I thank you, the World will thank you.”
Dr. Web Cavenee
Our Progress
Milestones We’ve Achieved Together
![US Trial Sites](https://www.nfcr.org/wp-content/uploads/2021/02/US-Trial-Sites--150x150.jpg)
38 Trial Sites in the United States
![Patients Enrolled](https://www.nfcr.org/wp-content/uploads/2021/02/Patients-Enrolled--150x150.jpg)
1500 Patients Screened
![Global Trial Sites](https://www.nfcr.org/wp-content/uploads/2021/02/Global-Trial-Sites-150x150.jpg)
30+ Global Sites Selected
![Untitled design(144)](https://www.nfcr.org/wp-content/uploads/2021/02/Untitled-design144-150x150.jpg)
6 Pharmaceutical Partners
In addition to the progress already achieved, the AGILE trial design will make an even greater impact. The AGILE trial approach will be used to combat other rare and deadly diseases, in the near future.